Legal & General Group
STOK icon

Legal & General Group’s Stoke Therapeutics STOK Stock Holding History

Legal & General Group’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17M Buy
35,705
+3,657
+11% +$117K ﹤0.01% 2142
2026
Q1 		$1.04M Sell
32,048
-4,318
-12% -$142K ﹤0.01% 2130
2025
Q4 		$1.15M Sell
36,366
-1,417
-4% -$42.6K ﹤0.01% 2178
2025
Q3 		$888K Buy
37,783
+6,706
+22% +$115K ﹤0.01% 2277
2025
Q2 		$353K Sell
31,077
-4,270
-12% -$40.5K ﹤0.01% 2532
2025
Q1 		$235K Hold
35,347
– – ﹤0.01% 2584
2024
Q4 		$390K Buy
35,347
+1,540
+5% +$18.9K ﹤0.01% 2546
2024
Q3 		$415K Buy
33,807
+1,017
+3% +$14.4K ﹤0.01% 2523
2024
Q2 		$443K Buy
32,790
+30,512
+1,339% +$412K ﹤0.01% 2457
2024
Q1 		$30.8K Sell
2,278
-851
-27% -$5.16K ﹤0.01% 2849
2023
Q4 		$16.5K Sell
3,129
-7,805
-71% -$33.4K ﹤0.01% 3108
2023
Q3 		$43.1K Sell
10,934
-4,258
-28% -$28K ﹤0.01% 2885
2023
Q2 		$161K Buy
15,192
+11,971
+372% +$127K ﹤0.01% 2783
2023
Q1 		$26.8K Sell
3,221
-3,077
-49% -$27.8K ﹤0.01% 2989
2022
Q4 		$58.1K Hold
6,298
– – ﹤0.01% 2925
2022
Q3 		$81K Buy
6,298
+1,056
+20% +$16.8K ﹤0.01% 2877
2022
Q2 		$69K Sell
5,242
-39
-0.7% -$592 ﹤0.01% 2941
2022
Q1 		$111K Hold
5,281
– – ﹤0.01% 2840
2021
Q4 		$127K Buy
5,281
+29
+0.6% +$692 ﹤0.01% 2857
2021
Q3 		$134K Buy
5,252
+2,532
+93% +$70.6K ﹤0.01% 2789
2021
Q2 		$92K Buy
2,720
+715
+36% +$25.3K ﹤0.01% 2770
2021
Q1 		$78K Buy
2,005
+220
+12% +$12.5K ﹤0.01% 2687
2020
Q4 		$110K Sell
1,785
-555
-24% -$25.4K ﹤0.01% 2563
2020
Q3 		$79K Buy
2,340
+281
+14% +$8.02K ﹤0.01% 2552
2020
Q2 		$49K Sell
2,059
-559
-21% -$13.3K ﹤0.01% 2735
2020
Q1 		$60K Buy
2,618
+816
+45% +$20.2K ﹤0.01% 2547
2019
Q4 		$51K Buy
1,802
+312
+21% +$7.85K ﹤0.01% 2805
2019
Q3 		$32K Buy
+1,490
New +$41.5K ﹤0.01% 2940

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Legal & General Group's STOK Position: Q2 2026 in Review

Legal & General Group increased its Stoke Therapeutics (STOK) stake by 11% in Q2 2026, buying an estimated $117K and bringing the position to 35,705 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #2142.

Legal & General Group first reported a position in STOK in Q3 2019 and has held it in 28 quarters since. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Legal & General Group held 35,705 shares of Stoke Therapeutics worth $1.17M as of Q2 2026.
  • Legal & General Group bought 3,657 Stoke Therapeutics shares in Q2 2026, an estimated $117K.
  • Stoke Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2142 holding.
  • Legal & General Group first reported a position in Stoke Therapeutics in Q3 2019 and has held it in 28 quarters since.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.